Get more insight from the NOBLE Registry Website
Revealing the website of the NOBLE Registry : get more [...]
Q&A: How a new imaging tool helps to better stage prostate cancer
Q&A by Doctor Jeremie Calais on how PSMA PET imaging [...]
FDA for Lu-177-PSMA-617 for mCRPC treatment
Targeted Oncology, Sarah Karlovitch, June 17, 2021 The FDA has [...]
Drugmakers push into radio pharmaceuticals
Dolgin, E. Drugmakers go nuclear, continuing push into radiopharmaceuticals. Nat Biotechnol 39, 647–649 [...]
NOBLE: Tc-99m-iPSMA SPECT shows promising results
Promising results following the initial experience using Tc-99m-iPSMA led by [...]
Asco 2021 justifies Novartis’s radioligand Vision
Evaluate Vantage, Jacob Plieth, June 3, 2021 177Lu-PSMA-617 significantly improves [...]
EANM position paper on the role of radiobiology in nuclear medicine
Aerts, A., Eberlein, U., Holm, S. et al. EANM position [...]
PSMA theranostic Lu-177-PSMA-617 approaches prime time in mCRPC
Urology Times Journal, Jason M. Broderick - April 15, 2021 [...]
Noble Registry – iPSMA SPECT Imaging for Prostate Cancer
BRUSSELS, Belgium and MELBOURNE, Australia, 20th of April 2021 – [...]
Evolving role of Ac-225-PSMA Radioligand Therapy in mCRPC
225Ac-PSMA RLT is an efficacious and safe treatment option for [...]